Dr. Andrew Geall
RNA Vaccine Platform Leader
Andrew J. Geall, PhD is the RNA Vaccine Platform Leader at Novartis Vaccine and Diagnostics (Cambridge, USA). He has undergraduate degrees in Chemical Engineering and Pharmacy and completed his PhD in Gene Delivery at the University of Bath U.K. in 1999. Before joining Novartis in 2006, Dr. Geall was manager of the Pharmaceutics department at Vical (San Diego). He led the formulation development of the company’s DNA vaccine program and was responsible for production of the gene delivery systems for clinical trials. He joined Novartis Pharmaceutical AG to lead siRNA delivery efforts and in 2008 moved to the Vaccines Research division to establish the RNA Vaccine Platform and has made a major contribution to the patent estate for this novel technology. In addition, he is the corresponding author on several recent RNA vaccine publications.